LexisPSL
Crucial Development on the Presumption of Confidentiality in the Access to Document Saga (PTC Therapeutics v EMA and MSD Animal Health Innovation, Intervet v EMA)
September 19, 2019
The saga of access to documents (ATD) cases in the European pharmaceutical legal landscape continues, this time with two promising opinions of Advocate-General Hogan. In summary AG Hogan found that the General Court had erred in law in its conclusions that (a) there was no general presumption of confidentiality and (b) access to the study reports submitted in a marketing authorisation application dossier at issue would not compromise the applicants’ commercial interests.
This article has been originally published on LexisPSL.
Contacts

Capabilities
Suggested News & Insights
Life Sciences College 2027Thursday, February 4, 2027Exclusive Fireside Chat: A Conversation With FDA's Chief CounselTuesday, January 12, 2027Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027GMP 2026: Regulatory Reliance, AI, and the Future of Pharmaceutical ManufacturingWednesday, December 2, 2026Sidley Senior Managing Associate Jason Hyatt to Speak at PwC Life Sciences IPO Readiness WorkshopMonday, November 16, 2026Treasury Proposes to Prohibit U.S. Investment in Chinese Biotech: What It Means for China Licensing DealsNovember 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory